Physician profile
Christopher J Smith
NPI 1205837069
$1,194.58
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2020: $269 · 2021: $45.06 · 2023: $59.71 · 2024: $42.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $102.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $143.76 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $131.94 | 2019-2021 | |
| Neotract INC. | $129.03 | 2020 | |
| Merck Sharp & Dohme LLC | $119.05 | 2019 | |
| Abbvie INC. | $109.19 | 2019-2021 | |
| Pfizer INC. | $71.23 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.21 | 2019-2020 | |
| Allergan, INC. | $42.57 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $40.59 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.49 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $33.47 | 2019-2020 | |
| Abiomed | $27.42 | 2024 | Impella |
| Bausch Health US, LLC | $26.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.15 | 2019 | |
| Cranial Technologies, INC | $25.11 | 2023 | Doc Band |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $23.23 | 2019-2020 | |
| Amarin Pharma, INC. | $17.77 | 2019 | |
| Dexcom, INC. | $17.24 | 2021 | |
| Genentech USA, INC. | $15.14 | 2024 | Activase |
| Boston Scientific Corporation | $14.25 | 2023 | Wavewriter Alpha Prime 16 |
| Sobi, INC | $13.71 | 2019 | |
| Sanofi Pasteur INC. | $13.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.56 | 2019 | |
| Vanda Pharmaceuticals INC. | $12.16 | 2019 | |
| Glaxosmithkline, LLC. | $11.16 | 2019 | |
| Dynavax Technologies Corporation | $8.27 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.